Health and Healthcare
Medarex & Bristol-Myers Show Positive Metastatic Melanoma Data (BMY, MEDX)
Published:
There is some very hopeful data out there this morning on cancer survival. Bristol-Myers Squibb Co. (NYSE: BMY) and Medarex, Inc. (NASDAQ: MEDX) have released updated survival data from three Phase II studies of ipilimumab in patients with advanced metastatic melanoma in Stage III or IV levels who had previously been treated showing that approximately half of patients who received ipilimumab remained alive beyond one year.
The results are based on follow-up of the patient population fromstudies 008, 022 and 007 and show a consistent one-year survival ratebetween 47% and 51% as follows:
Currently shares are up over 2% at $7.05. If the markets weren’t doingso poorly today on the bailout mergers and failures in the financialstocks then this might be getting more attention.
Jon C. Ogg
September 15, 2008
Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Get started right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.